The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

• Type of Material: Article
• Authors: N Shah, University of California San Francisco; J Aiello, Patient Empowerment Network; DE Avigan, Beth Israel Deaconess Medical Center; JG Berdeja, Sarah Cannon Research Institute; IM Borrello, Sidney Kimmel Comprehensive Cancer Center; A Chari, Icahn School of Medicine at Mount Sinai; AD Cohen, University of Pennsylvania; K Ganapathi, University of California San Francisco; L Gray, University of California San Francisco; D Green, Fred Hutchinson Cancer Research Center; A Krishnan, City Hope Comprehensive Cancer Center; Y Lin, Mayo Clinic; E Manasanch, University of Texas MD Anderson Cancer Center; NC Munshi, Harvard Medical School; Ajay Nooka, Emory University; AP Rapoport, University of Maryland; EL Smith, Memorial Sloan Kettering Cancer Center; R Vij, Washington University in St. Louis; Madhav Dhodapkar, Emory University
• Language: English
• Date: 2020-01-01
• Publisher: BMJ PUBLISHING GROUP
• Publication Version: Final Published Version
• Copyright Statement: © Author(s) (or their employer(s)) 2020.
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1136/jitc-2020-000734
• Title of Journal or Parent Work: JOURNAL FOR IMMUNOTHERAPY OF CANCER
• Volume: 8
• Issue: 2
• Grant/Funding Information: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
• Keywords: Oncology; CYTOKINE RELEASE SYNDROME; ANTIBODY-DRUG CONJUGATE; MONOCLONAL-ANTIBODY; MINIMAL RESIDUAL DISEASE; receptors; MATURATION ANTIGEN; OPEN-LABEL; BRENTUXIMAB VEDOTIN; Science & Technology; T-CELL THERAPY; immunotherapy; PLUS POMALIDOMIDE; antineoplastic protocols; chimeric antigen; LOW-DOSE DEXAMETHASONE; hematological neoplasms; Life Sciences & Biomedicine; Immunology; guidelines as topic
• Research Categories: Health Sciences, Pathology; Health Sciences, Oncology; Health Sciences, Immunology

Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.